Ad
related to: cap molecular oncology- Add a Testing Line
Already have a clinical lab?
Learn how we can add a testing line
- About Us
Full-service medical lab consulting
Unparalleled reach and resources.
- Lab Instrument Services
Qualified lab instrument engineers.
Experienced application scientists.
- Contact Us
Ready to get started?
Get your free consultation today!
- Add a Testing Line
Search results
Results from the WOW.Com Content Network
Catabolite activator protein (CAP; also known as cAMP receptor protein, CRP) is a trans-acting transcriptional activator that exists as a homodimer in solution. Each subunit of CAP is composed of a ligand -binding domain at the N-terminus (CAP N , residues 1–138) and a DNA-binding domain at the C-terminus (DBD, residues 139–209).
Molecular oncology has identified genes that are involved in the development of cancer. The research combined diverse techniques ranging from genomics, computational biology, tumour imaging, in vitro and in vivo functional models to study biological and clinical phenotypes.
The College of American Pathologists (CAP) is a member-based physician organization founded in 1946 comprising approximately 18,000 board-certified pathologists. It serves patients, pathologists, and the public [ 1 ] by fostering and advocating best practices in pathology and laboratory medicine.
In 2013, Batut et al. [13] combined CAP trapper, template switching, and 5′-phosphate-dependent exonuclease digestion in RAMPAGE to maximize promoter specificity. In 2014, Murata et al. [ 14 ] published the nAnTi-CAGE protocol, where capped 5′ ends are sequenced on the Illumina platform with no PCR amplification and no tag cleavage.
Studies show that, in prostate cancer, [12] nasopharyngeal carcinoma, [13] hepatocellular carcinoma, [14] and breast cancers, [15] NCAPH is commonly over-expressed, and may be used as a biomarker for various cancer types and a viable prognostic factor for identification and potential drug targeting.
HAMLET (human alpha-lactalbumin made lethal to tumor cells) is a molecular complex derived from human breast milk that kills tumor cells by a process resembling programmed cell death . As of 2008 [update] , it had been tested in humans with skin papillomas and bladder cancer .
LNCaP cells are a cell line of human cells commonly used in the field of oncology. LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis from a 50-year-old caucasian male in 1977. They are adherent epithelial cells growing in aggregates and as single cells. [1]
This phenomenon, the process of which is called cap formation, was discovered in 1971 on lymphocytes [1] and is a property of amoebae and all locomotory animal cells except sperm. The crosslinking is most easily achieved using a polyvalent antibody to a surface antigen on the cell.
Ad
related to: cap molecular oncology